« A disruptive technology, which can be applied in the treatment of numerous conditions »
> Press releases 2023
Theranexus publishes its cash position as of September 30th 2023
17/10/2023
Download PDF File (<1 Mo)
Highly Promising 12-month results in the Phase I/II trial of Batten-1
29/09/2023 07:30
Download PDF File (<1 Mo)
Theranexus announces first half 2023 financial results
28/09/2023 18:00
Download PDF File (<1 Mo)
Information on the number of shares composing share capital
30/08/2023 18:00
Download PDF File (<1 Mo)
Theranexus raises around 3.1 million euros in fundraising
11/07/2023 - 07.30 AM CET
(<1Mo)
Theranexus launches a global offering for an amount of c. 4 million euros and welcomes the American Beyond Batten Disease Foundation as a new shareholder
11/07/2023
(<1Mo)
Encouraging preliminary 6-month results in the Phase I/II trial of Batten-1 in Batten disease (CLN3)
14/06/2023 7.30 AM CET
(<1Mo)
Theranexus and BBDF granted positive opinion by EMA for the design of Phase III trial to evaluate Batten-1 in CLN3 Batten disease
07/06/2023 7.30 AM CET
(<1Mo)
Theranexus and BBDF win FDA approval on efficacy endpoints for the Phase III trial to
evaluate Batten-1 in CLN3 Batten disease
09/05/2023 7.30 AM CET
(<1Mo)
THERANEXUS publishes its 2022 full-year results and presents an update on its programs
12/04/2023 6PM CET
(<1Mo)
Information on the number of shares composing share capital
04/04/2023
Download PDF File (276Ko)
THERANEXUS, BBDF and Cardiff University present their novel research on Batten-1 and Batten disease at Worldsymposium 2023
20/02/2023 6PM CET
(<1Mo)
AISTROSIGHT: New joint project team between Theranexus, INRIA, Claude Bernard University Lyon 1 and Hospices Civils de Lyon targeting rare neurological diseases
10/02/2023 before market opens
(<1Mo)
THERANEXUS publishes its cash position as of 31 December 2022 and announces organizational changes
18/01/2023 before market opens
(<1Mo)
New advance to the Theranexus and BBDF Batten-1 program for juvenile Batten disease (CLN3)
05/01/2023
(<1Mo)